Volunteer Screening for Vaccine and Antivirals Clinical Trials
NCT01593709 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 359
Last updated 2021-08-02
Summary
Background:
\- Vaccines and antiviral therapies are critical for preventing and treating viral diseases. Testing these vaccines and drugs often requires healthy volunteers. To ensure that volunteers are healthy and eligible to participate in these studies, they will be screened before the start of the study. This screening may involve a medical history, physical exam, and blood test. Other samples may also be collected. This study will help identify volunteers who are eligible to participate in vaccine or antiviral therapy trials.
Objectives:
\- To screen volunteers for clinical trials of vaccines or drugs to treat or prevent virus infections.
Eligibility:
\- Healthy volunteers at least 18 years of age.
Design:
* Screening may begin several months before the start of the clinical trial. Participants may come to the National Institutes of Health clinic one or more times.
* Participants may be screened with a physical exam and medical history. Blood samples will be collected. Other samples may also be collected, including urine, nasal wash, nasal swab, or stool samples. All samples will be stored for reference by the study researchers....
Conditions
- Normal Physiology
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Jeffrey I Cohen, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-11-27
- Primary Completion
- 2021-07-21
- Completion
- 2021-07-21
Countries
- United States
Study Locations
More Related Trials
-
A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults
NCT00942071 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
NCT00329927 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
NCT05078905 ·Status: RECRUITING
-
Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
NCT02148328 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
NCT03859141 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
NCT00973349 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
NCT00929331 ·Status: COMPLETED ·Phase: PHASE3
-
Influenza Challenge Study in Healthy Volunteers
NCT02746211 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine
NCT01617239 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
NCT00848029 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
NCT02233816 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011
NCT01152814 ·Status: COMPLETED ·Phase: PHASE2
-
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
NCT00995982 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects
NCT01356316 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
NCT01688297 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trials of Quadrivalent Influenza Vaccine
NCT06824519 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route
NCT03845231 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
NCT00644059 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT05823974 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
NCT05284851 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)
NCT03853993 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity Study of the Influenza Vaccine in Adults
NCT00258934 ·Status: COMPLETED ·Phase: PHASE2
-
PET-CT Scans in Healthy Volunteers After Flu Vaccination
NCT00769002 ·Status: TERMINATED ·Phase: NA
-
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
NCT00848848 ·Status: COMPLETED ·Phase: PHASE1